Heart valve disease associated with treatment with ergot-derived dopamine agonists: A clinical and echocardiographic study of patients with Parkinson's disease

Journal of Internal Medicine

Volumn 263, Issue 1, 2008, Pages 90-98

  Rasmussen, V G ^a   Poulsen, S H ^a   Dupont, E ^a   Ostergaard K ^a   Safikhany, G ^b   Egeblad, H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b HOLSTEBRO HOSPITAL   (Denmark)

Author keywords

Dopamine agonists; Ergolines; Fibrosis; Parkinson's disease; Valvular heart disease

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ADULT; AGED; AORTA VALVE REGURGITATION; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART MURMUR; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PARKINSON DISEASE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; CROSS-SECTIONAL STUDIES; DENMARK; DOPAMINE AGONISTS; ELECTROCARDIOGRAPHY; ERGOLINES; ERGOT ALKALOIDS; FEMALE; HEART VALVE DISEASES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 37449031645     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01874.x     Document Type: Article

References (25)

1. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997 337 : 581 8.
2. Kancherla MK, Salti HI, Mulderink TA, Parker M, Bonow RO, Mehlman DJ. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol 1999 84 : 1335 8.
3. Sachdev M, Miller WC, Ryan T, Jollis JG. Effect of fenfluramine- derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 2002 144 : 1065 73.
4. Wilke A, Hesse H, Hufnagel G, Maisch B. Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine. Eur Heart J 1997 18 : 701.
5. Fitzgerald LW, Burn TC, Brown BS et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000 57 : 75 81.
6. Gustafsson BI, Tommeras K, Nordrum I et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005 111 : 1517 22.
7. Rajamannan NM, Caplice N, Anthikad F et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 2001 10 : 827 31.
8. Setola V, Hufeisen SJ, Grande-Allen KJ et al. 3, 4- methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003 63 : 1223 9.
9. Newman-Tancredi A, Cussac D, Quentric Y et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002 303 : 815 22.
10. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB, Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004 63 : 301 4.
11. Flowers CM, Racoosin JA, Lu SL, Beitz JG. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003 78 : 730 1.
12. Junghanns S, Fuhrmann JT, Simonis G et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 2007 22 : 234 8.
13. Kim JY, Chung EJ, Park SW, Lee WY. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord 2006 21 : 1261 4.
14. Peralta C, Wolf E, Alber H et al. Valvular heart disease in Parkinson's disease vs. controls: an echocardiographic study. Mov Disord 2006 21 : 1109 13.
15. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002 77 : 1280 6.
16. Van Camp G, Flamez A, Cosyns B et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004 363 : 1179 83.
17. Waller EA, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005 80 : 1016 20.
18. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006 67 : 1225 9.
19. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007 356 : 29 38.
20. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007 356 : 39 46.
21. Lancellotti P, Lebrun F, Pierard LA. Determinants of exercise-induced changes in mitral regurgitation in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2003 42 : 1921 8.
22. Zoghbi WA, Enriquez-Sarano M, Foster E et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003 16 : 777 802.
23. Nielsen LS, Svanegaard J, Klitgaard NA, Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 2004 6 : 63 70.
24. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984 70 : 657 62.
25. Singh JP, Evans JC, Levy D et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 1999 83 : 897 902.